2006年-世界发展银行全球_An_Analysis_of_Recurrent_Costs_of_the_Free_ART_Programme_of_the_Government_of_India_58页_1mb

Summary of "An Analysis of Recurrent Costs of the Free ART Programme of the Government of India"

Core Content

This report, authored by Indrani Gupta, Mayur Trivedi, and Subodh Kandamuthan, provides a detailed analysis of the recurrent costs associated with India's Free Antiretroviral Treatment (ART) program. The study was conducted by the Institute of Economic Growth (IEG) in Delhi, with funding from the World Bank and support from the National AIDS Control Organization (NACO), and aims to support financial sustainability planning (FSP) for the national ART program.

Main Objectives and Rationale

• To estimate the recurrent financial costs of the Free ART program across selected government hospitals in India.
• To understand the distribution of these costs among various entities, including NACO, State AIDS Control Societies (SACS), hospitals, and state governments.
• To assess the impact of cost-saving measures, such as reducing ARV and CD4 test kit prices, on the overall financial burden.
• To identify the out-of-pocket expenditures borne by patients and their implications for treatment adherence and program effectiveness.
• To provide a baseline for future financial planning and expansion of the program.

Key Findings

• Average per client recurrent cost: Rs. 1,264 per month or Rs. 15,168 ($353) per year.
• Cost components:
  • ARV drugs: 46% of total cost
  • CD4 kits and reagents: 24%
  • Human resources: 22%
  • Hospital support: 5%
  • OI drugs: 3%
• Cost distribution across entities:
  • NACO: 47%
  • SACS: 35%
  • Hospitals: 18%
• Patient out-of-pocket costs:
  • Approximately Rs. 900 ($21) per month.
  • About 25% of this is spent on food and nutrition.
• Societal cost:
  • About Rs. 50 ($1.15) per client per month.
• Impact of cost reductions:
  • If NACO reduces ARV and CD4 test kit prices by 50%, the per client cost could decrease by 23%.
  • Centralizing drug and CD4 test kit purchases would shift the cost burden to NACO, increasing its share to 78%.
• Total program costs over 5 years:
  • At current unit costs: $215 million
  • With 50% price reduction: $140 million

Methodology

• The study involved seven selected hospitals across six high-prevalence states and Delhi.
• Costs were calculated from the financial perspective, excluding economic costs using shadow prices.
• The methodology included:
  • Collecting cost data from NACO and SACS.
  • Identifying and analyzing major departments involved in treating ART patients (e.g., Medicine, Skin/STD, Gynecology).
  • Gathering data on diagnostic tests and their frequency.
  • Collecting departmental expenditure data.
  • Allocating costs based on volume of ART patients.
  • Conducting 264 patient interviews to assess out-of-pocket expenses.

Limitations

• The study focused on financial costs, not economic costs.
• Capital costs were excluded due to data unavailability and the belief that they are less relevant for policy planning.
• Some shared costs were not fully accounted for due to the complexity of data collection.
• The analysis did not consider all potential cost-saving opportunities or future expansion scenarios in depth.

Future Projections and Recommendations

• The estimated costs were used to simulate future program expenses over the next five years.
• The report highlights the need for:
  • Financial planning to support scaling up.
  • Cost-effectiveness analysis for second-line ART programs.
  • Improved data management to enhance transparency and efficiency.
  • Policy considerations on cost-sharing between NACO, SACS, hospitals, and state governments.
  • Support for patients in terms of transport and nutrition to improve adherence.

Conclusion

This study provides a baseline for financial planning and offers insights into the cost structure of India's Free ART program. It emphasizes the importance of cost transparency, sustainability planning, and policy coordination among stakeholders. The findings can be used by policymakers, planners, and stakeholders to improve the efficiency and effectiveness of the ART program, and to ensure that the financial burden is managed appropriately as the program scales up.

Annexes and References

• The report includes annexes with detailed data and methodology.
• References to various studies and reports, including those from Bastos et al (2001), Boulle et al (2003), Comber et al (2004), and Kombe et al (2003), are included to support the analysis.

Key Entities and Sites

• Selected hospitals:
  • Government Hospital of Thoracic Medicine (GHTM), Chennai
  • Regional Institute of Medical Sciences (RIMS), Imphal
  • BJ Medical College, Ahmedabad
  • Lok Nayak Jai Prakash (LNJP) Hospital, New Delhi
  • Ram Manohar Lohia (RML) Hospital, New Delhi
  • Government Medical College and Hospital, Trivandrum
  • Government Medical College and Hospital, Thrissur
• Other entities:
  • NACO
  • SACS
  • Private sector
  • NGOs
  • Intersectoral partners

Implications

• The results can be used to inform financial sustainability planning for the national ART program.
• They offer a benchmark for comparing with other studies and for policy refinement.
• The study also highlights the importance of patient-centered cost analysis and the need for transparent and efficient resource management.